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Abstract
Background: High-risk human papillomavirus (HR HPV) testing has been shown to be a valuable tool in cervical
cancer screening for the detection of cervical pre-cancer and cancer.
Methods: We report a purely observational study evaluating HR HPV prevalences in residual liquid-based cytology
(LBC) samples using both the Cervista HPV HR Test and the Digene Hybrid Capture 2 High-Risk HPV DNA Test
(HC2) in a sample of 1,741 women aged ≥30 years of a German routine screening population of 13,372 women.
Test characteristics were calculated and a novel method for measuring test performances was applied by calculating
ratios of sensitivity or specificity.
Results: The overall agreement of both tests for detection of HR HPV was excellent (κ = 0.8). Relative sensitivities for
the detection of histologically confirmed severe cervical intraepithelial dysplasia (CIN3+) were similar for both
HPV-tests, which was confirmed by the ratio analysis. However, discrepancy analysis between the Cervista HPV HR
test and HC2 revealed a high false positive rate of the Cervista HPV HR test in the cytology normal category.
Conclusions: Performance of the Cervista HPV test in cervical specimens with abnormal cytology is comparable to
HC2 as both tests were highly sensitive and specific for the detection of high grade cervical disease. We also
demonstrate evidence that modification of the cut-off values drastically reduces the false positive rate in the
cytology normal category without affecting the detection of CIN3+, which ultimately improved specificity of the
Cervista HPV HR assay.
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Background
In Germany, the cervical cancer mortality rate has notably
decreased since the introduction of gynaecological screen-
ing for cervical cancer in 1971 [1]. Annual opportunistic
screening is usually performed by conventional cytology
(Pap-smear) and is covered by health insurances for
women aged 20 years or older. Nevertheless, 4,900 new
cases and approximately 1,600 deaths of cervical cancer
are observed each year [2] and 150,000 cases of cervical
cancer precursors (CIN3) are diagnosed [3]. Cervical can-
cer accounts for 1.6% of all cancer deaths among women
in Germany [2].
Persistent infection with high-risk human papillomavi-
ruses (HR HPV) has been shown to be necessary for the de-
velopment of cervical precancerous lesions and cancer [4].
Notably, the HR HPV types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58 and 59 have been defined as class I carcinogens
and HPV type 68 as class IIa carcinogens by the IARC [5].
The majority of all cervical cancer cases are associated with
the HR HPV types 16 and 18 [6]. The fact that HR HPV is
the causative infectious agent of cervical cancer has led to
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the development and investigation of various HPV detection
methods; and testing for HR HPV in addition to cytology is
nowadays applied in cervical cancer screening [7-9]. Three
DNA-based tests for the detection of the HR HPV group
and one RNA-based assays for HPV detection have been
approved by the US Food and Drug Administration
(FDA) for routine cervical cancer screening (http://www.
fda.gov/MedicalDevices/ProductsandMedicalProcedures/
InVitroDiagnostics/ucm330711.htm). Among these are
the Digene Hybrid Capture 2 High-Risk HPV DNA test
(HC2; QIAGEN, Hilden, Germany), the Cervista HPV HR
test (CER; Hologic, Madison, WI), the cobas HPV Test
(Roche, Pleasanton, USA) and the RNA-based APTIMA
HPV Assay (Hologic, San Diego, CA). The cobas HPV
Test has recently been approved for primary screening by
the FDA (www.fda.gov).
The HC2 test for the collective detection of at least 13
carcinogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68) [10] is a nucleic acid hybridisation assay
with signal amplification using microplate chemilumin-
escence for semi-quantitative detection of HPV-DNA in
cervical specimens. In addition to the 13 carcinogenic
HPV types detected by HC2, the Cervista HPV HR
assay also detects putative HR HPV type 66 [11]. The
test principle employs the Invader chemistry, which is
a signal amplification method recognizing specific nu-
cleic acid sequences.
Performance comparisons of HR HC2 and the Cervista
HPV HR test have previously been performed [12-22].
However, only a limited number of studies present data
from both assays on the same residual LBC sample in
comparison to cytology and histology results [12,16,17,19].
The objective of this study was therefore to evaluate the
Cervista HPV HR assay in comparison to HC2 regarding
relative sensitivity and specificity for the detection of high
grade CIN3+ in women of a German routine screening
population aged ≥30 years using cervical samples collected
in PreservCyt LBC medium. PreservCyt LBC cervical
samples from 1,741 women with abnormal (n = 468),
ASC-US (n = 20) as well as a random sample of women
with normal cytology (n = 1,208) were analyzed by the
Cervista HPV HR test and HC2.
Methods
Study design
The study was conducted in a routine screening popu-
lation of 13,372 women ≥ 30 years of age living in the
Hannover area of Germany (Figure 1). Cervical samples
were collected in PreservCyt Pap Test specimen collection
medium (Hologic, Marlborough, MA) between February
Figure 1 Study design flowchart.
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and June 2011 and cytology was tested within one week
after collection in a central services laboratory (Amedes,
Bad Mnder, Germany). As determined by the ethics com-
mittee (Ethikkommission bei der Deutschen rztekammer
Niedersachsen), no ethical approval was required for this
purely observational study, because residual patient sam-
ples were used that were completely anonymized and
study results had no influence on the patients follow-up
strategy. A total of 2,303 liquid based cytology (LBC)
smears including all residual samples with abnormal and
ASC-US cytology results as well as 10% of randomly se-
lected normal LBC samples were sent to Tbingen for
HPV testing.
After exclusion of ineligible samples a total of 1,741
specimens from women with abnormal, ASC-US and
normal cytology were analyzed both by the Cervista
HPV HR assay and by the Digene Hybrid Capture 2
High Risk DNA Test. This collection also included 60
samples of patients with CIN3+, which were added to
the cohort in order to obtain a higher CIN3+ rate.
Samples with discordant HPV test results were genotyped
by INNO-LiPA HPV Genotyping Extra for discrepancy
analysis. Participants were blinded for their HPV test re-
sults, and colposcopy and histopathology was only per-
formed when indicated. Samples with a primary histology
of CIN2+ were independently reviewed.
Sample collection
According to routine guidelines all clinical samples were
collected in LBC PreservCyt Collection medium (Hologic)
using the Cervex broom and were subsequently tested by
cytology in the central cytology laboratory within one
week of collection.
Liquid based cytology
All samples were tested by the ThinPrep 2000 Proces-
sor (Hologic) following the manufacturer s instruc-
tions. Cytology results were reported using the Munich
Nomenclature II and were translated into The Bethesda
System (TBS) (Table 1). LBC results were considered
negative when the result was Pap I/II or Pap IIw; all other
results were considered positive.
DNA extraction and HPV testing
Residual LBC samples were sent to the central molecular
testing laboratory (UKT, Tbingen) within 2 weeks of col-
lection for HPV testing. For testing by Cervista HPV HR
assay, DNA extraction was performed on 2ml of each
ThinPrep sample using the GenFind DNA Extraction Kit
in combination with the ThinPrep 5000 STS (Sample
Transfer System, (Hologic). To test for a possible risk of
cross-contamination during sample transfer by the STS,
we ran a pilot experiment with alternating blank samples
and samples containing HPV16-positive SiHa cells and
found no evidence of cross-contamination. DNA extrac-
tion was carried out according to the manufacturer s in-
structions. DNA integrity was measured by PCR using
primers targeting the human β-globin gene. Using the Cer-
vista high throughput automation (HTA) system DNA
samples (10 μl per reaction) were then tested by Cervista
HPV HR assay, which was performed in compliance with
the manufacturer s instructions. The current cut-off defini-
tions were used in this study, which were calculated as per
the manufacturer s instructions. Briefly, a signal-to-noise
value was generated for each of three reactions, which is
referred to as Fold-Over-Zero (FOZ). A FOZ ratio was cal-
culated by dividing the highest by the lowest FOZ value of
the three reactions. A given sample was considered HPV-
positive if the HPV FOZ ratio was ≥1.525. When the FOZ
ratio was <1.525, but all three individual reaction FOZ
values were ≥1.93, the sample was also considered positive
for HPV.
4ml of each ThinPrep sample were processed for HR
HC2 testing, which was performed using the Rapid Cap-
ture System 1 (RCS-1) according to the manufacturer s in-
structions. The cut-off value of RLU/CO = 1, equivalent to
Table 1 Results LBC versus histology and HPV testing
Primary Histology (N = 139)
Not performed Normal Borderline CIN1 CIN2 CIN3+ Total
LBC N(Cer+,HC2+) N(Cer+,HC2+) N(Cer+,HC2+) N(Cer+,HC2+) N(Cer+,HC2+) N(Cer+,HC2+) N(Cer+, HC2+)
Normal (Pap I/II) 1,208 (130, 69) 0 0 0 0 0 1,208 (130, 69)
ASC-US (Pap IIw) 65 (20, 18) 0 0 0 0 0 65 (20, 18)
ASC-H, AGUS (Pap III) 14 (6, 5) 0 1 (0, 0) 0 0 5 (4, 4) 20 (10, 9)
LSIL, HSIL (Pap IIID) 312 (197, 211) 21 (16, 18) 1 (1, 1) 5 (4, 4) 13 (12, 13) 20 (20, 20) 372 (250, 267)
HSIL, CIS (Pap IVa) 3 (3, 3) 1 (1, 1) 0 3 (3, 3) 6 (6, 6) 58 (56, 58) 71 (69, 71)
HSIL, CIS, Micro (IVb) 0 0 0 0 0 2 (2, 2) 2 (2,2)
Microinvasive (Pap V) 0 0 0 0 0 3 (3, 3) 3 (3, 3)
Total 1,602 (356, 306) 22 (17, 19) 2 (1, 1) 8 (7, 7) 19 (18, 19) 88 (85, 87) 1,741 (484, 439)
Cer+: Cervista positive; HC2+: HC2 positive.
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1pg HPV DNA per 1ml of sampling buffer for positive test
results, was used in this study. PreservCyt specimens
were retested when RLU/CO ratios between ≥1.0 and <2.5
were obtained. If the initial retest result was positive
(RLU/CO of ≥1.0), the specimen was reported as posi-
tive . If the retest was negative (RLU/CO of <1.0), a sec-
ond repeat test (third result) was performed to generate a
final result.
HPV genotyping was carried out using the INNO-
LiPA HPV Genotyping Extra test as previously de-
scribed [23].
Histology review
All samples with a primary histology result of CIN2+
were reviewed by an independent external expert. In
case of a discrepant review reading, a second histology
review was performed. If two out of three diagnoses
were identical, the result was considered final.
Statistical analysis
Statistical analysis was performed on all samples with
valid test results from LBC, the Cervista HPV HR test
and HC2 (N = 1,741). Cohens kappa value (κ) was used
to calculate the agreement between the Cervista HPV
HR test and the HC2 test. 95% confidence intervals (CI)
for HPV prevalence were calculated using the Wilson
score method. McNemar s test for comparison of two
proportions was used for calculating two-sided P-values
to assess statistical significance of different Cervista
HPV HR and HC2 test results. In addition, relative sen-
sitivities and specificities as well as positive predictive
values (PPV) and negative predictive values (NPV) based
on cytological results and histology were calculated ac-
cording to Cuzick et al. [24]. The statistics software
package R version 3.0.2. was used for statistical analyses.
Ratio analysis of sensitivities and specificities
Relative performance of the tests were measured by cal-
culating the ratio of sensitivity and the ratio of specifi-
city. The ratio of two sensitivities is the True Positive
rate of test 1 divided by the True Positive rate of test 2.
The ratio of two specificities depends on the prevalence,
which in this case was Spec(CER)/Spec(HC2) = (0.77
Prevalence)/(0.80 Prevalence). A full description of
this method can be found in the Additional file 1. Confi-
dence intervals were calculated using the delta method
transform on the proportion s confidence interval. The
ratio analysis has been performed using the statistics
software package R version 3.0.2.
Results
Out of 2,303 overall specimens, a total of 562 were ex-
cluded due to inadequacy (n = 196), insufficient material
(n = 262) or because study participants were younger
than 30 years (n = 104; Figure 1). The 1,741 remaining
specimens were analysed by both the Cervista HPV HR
assay and HC2. 468 of these samples had an abnormal
cytology result (Pap ≥ III), 65 were classified ASC-US
(Pap IIw) and 1,208 women were cytologically normal
(Pap I/II) (Table 1). Colposcopy and histopathology was
performed on 139 patients with abnormal cytology re-
sults and was not performed on cytologically normal
women due to the purely observational study design. A
high CIN3+ rate was obtained by including 60 additional
patients with confirmed CIN3+.
HPV prevalence detected by the Cervista HPV HR test and
HC2
Concordant results were obtained from 1,608 (92.4%) of
1,741 LBC samples (Table 2). The agreement between
the tests was excellent at κ = 0.8 (95% CI: 0.77-0.84).
Overall HPV detection rates by the Cervista HPV HR
test and HC2 for all LBC categories are summarized in
Table 3. In women with normal LBC results, HR HPV
was detected in 10.8% of the specimens by the Cervista
HPV HR test and in 5.7% using the HC2 test (κ = 0.53
(0.43-0.61)). HPV prevalence detected in the ASC-US
category (Pap IIw) was 30.8% for the Cervista HPV HR
assay and 27.7% for HC2, respectively. For category
ASC-H and AGUS (Pap III), Cervista HPV HR test-
positivity was 50% compared to 45% for HC2; for LSIL,
HSIL (Pap IIID) 67.2% and 71.8% and for HSIL, CIS
(Pap IVa) 97.2% and 100%, respectively. 100% HPV-
positivity was determined for both tests in the cytology
categories HSIL (Pap IIID), CIS (IVb) and microinvasive
(Pap V). Interestingly, kappa values (κ) calculated to
measure the agreement of both HPV tests were only fair
(κ ≤ 0.55) for LBC categories ≤ASC-US (≤Pap IIw). For
categories AGUS+ (≥Pap III) the agreement was excel-
lent (0.83 (0.77-0.88); Table 3).
Discrepancy analysis
A total of 133 discordant samples were detected between
the Cervista HPV HR test and HC2 (Table 4). 89 discrep-
ant samples (66.9%) were Cervista HPV HR test-positive
and HC2-negative compared to only 44 samples (31.7%)
with HC2-positive and Cervista-negative test results. The





Positive 395/22.7% 89/5.1% 484/27.8%
CER Negative 44/2.5% 1,213/69.7% 1,257/72.2%
Total 439/25.2% 1,302/74.8% 1,741/100%
The overall agreement between Cervista (CER) and HC2 test results was κ = 0.8
(95% CI: 0.77-0.84).
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majority of discordant results (n = 89) was detected in
specimens with normal cytology, followed by the LSIL and
HSIL category. Within the Pap normal category, 84.3% of
the discordant samples were CER- positive and HC2-
negative in contrast to the PapIIID (LSIL, HSIL) group
where 79.3% of the discordant samples were positive by
HC2 and negative by Cervista HPV HR-test results.
By genotyping of all deviant samples (n = 133) using
the INNO-LiPA HPV Genotyping Extra test (Table 5),
we resolved 56 HC2-negative and 3 CER-negative sam-
ples as true negatives revealing an unexpectedly high
number of false positive results for Cervista (n = 56).
While a total of 21 samples were inadequate for LiPA
genotyping, all remaining samples (n = 53) were HPV
DNA positive. In detail, 16 specimens missed by Cervista
contained non-target types of the Cervista HPV HR
assay (including 2 HPVX types) and a total of 23 sam-
ples (52.3%) were false-negative by Cervista. These in-
cluded 3 specimens with CIN2+ histology. In contrast, 7
discordant samples (7.9%) with negative HC2 and posi-
tive Cervista HPV HR test results were false-negative by
HC2, while another 7 samples contained non-target
types of the HC2 test (including 2 HPVX types). However,
none of the samples missed by HC2 had a histology result
of CIN2+.
Sensitivity and specificity
Relative sensitivity and specificity were calculated in order
to measure clinical outcomes related to HPV test results.
A total of 139 biopsies were taken from patients with ab-
normal cytology when indicated and analysed by histopath-
ology (Table 1). Overall relative sensitivity for detection of
histologically confirmed CIN3+ in patients with abnormal
cytology (AGUS+) was 96.6% for the Cervista HPV HR test
and 98.9% for the HC2 test (Table 6). Relative specificity
and PPV for Cervista HPV HR test were 15.7% and 66.4%
or 9.8% and 65.4% for HC2 test, respectively.
As only women with high grade abnormal cytology were
referred to colposcopy and considering the low sensitivity
of cytology in detecting CIN3+ [25], the true extent of
high grade CIN in the Pap I/II and IIw categories remains
unknown. This lack of data prevents the application of
conventional clinical sensitivity and specificity calcula-
tions. However, by calculating the ratio of the sensitivity
or specificity of two tests, we developed a method, which
yields a value that measures relative performance. The ra-
tio of sensitivity between Cervista HPV HR test and HC2
is 0.977 (0.69, 1.27). The ratio of specificity also contained
1 over all prevalence possibilities. Figure 2 shows the ratio
of specificity given a range of prevalences. As a result,
there is no statistical difference between clinical sensitivity
and specificity of the Cervista HPV HR test and HC2 for
the detection of high grade disease at the 95% confidence
level.
N = 100 histology reviews of slides with a primary hist-
ology result of CIN2+ were performed in the 19 CIN2
samples and in 81 of the 88 CIN3+ samples. Due to the
review 5 samples changed from CIN2 to the final result
CIN3 and one sample changed from a primary histology
result CIN3 to a final histology CIN2. Sensitivity and
specificity results for the performance of the Cervista
HPV HR test versus HC2 with regard to the endpoint
CIN3+ did not change when the review results were
accounted for in the calculations (data not shown).
Different Cervista cut-off values reduce HPV-positivity
without affecting detection of CIN3+
We found a significantly higher positivity rate of the
Cervista HPV HR test (10.8% positive results for Cervista
versus 5.7% for HC2; p <0.0001) in cytologically normal
women (Table 3) and discrepancy analysis revealed that
56 true-negative samples were false-positive by Cervista.
Therefore, we also calculated HPV positivity as detected by
the Cervista HPV HR test using two different modified cut-
off criteria (Table 7), which were selected for the detection
of CIN3+ lesions. The manufacturer-recommended cut-off
is a Fold-Over-Zero (FOZ) ratio of ≥1.525 or <1.525 in
Table 3 HPV prevalence detected by Cervista and HC2 in
comparison to LBC
LBC CER+ve (%) HR HC2+ve (%) κ (95% CI)
Normal (Pap I/II) 10.8% 5.7% 0.53 (0.43-0.61)
ASC-US (Pap IIw) 30.8% 27.7% 0.55 (0.33-0.78)
ASC-H, AGUS (Pap III) 50.0% 45.0% 0.9 (0.71-1.0)
LSIL, HSIL (Pap IIID) 67.2% 71.5% 0.82 (0.75-0.88)
HSIL, CIS (Pap IVa) 97.2% 100 % 1
HSIL, CIS, Micro (IVb) 100% 100% 1
Microinvasive (Pap V) 100% 100% 1
AGUS+ (≥Pap III) 71.3% 75.2% 0.83 (0.77-0.88)
HSIL+ (≥Pap IVa) 100% 100% 1
Total 27.8% 25.2% 0.8 (0.77-0.84)
+ve: positive; +: and higher.
95% CI for HPV prevalence were calculated using the Wilson Score method.






Normal (Pap I/II) 75/84.3% 14/15.7% 89
ASC-US (Pap IIw) 7/58.3% 5/41.7% 12
ASC-H, AGUS (Pap III) 1/100.0% 0 1
LSIL, HSIL (Pap IIID) 6/20.7% 23/79.3% 29
HSIL, CIS (Pap IVa) 0 2/100.0% 2
Total 89 44 133
+ve: positive; −ve: negative.
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Table 5 Discordant HPV test results resolved by their HPV genotype detected by INNO-LiPA genotyping
HPV genotype HPV classification HR HC2-ve, CER+ve (N) CER-ve, HR HC2+ve (N) Histology CIN2+ (HC2-ve/CER-ve)
HPV16* HR 4 4 0/2
HPV18* HR 0 1 0/1
HPV31* HR 0 3 0
HPV33* HR 0 1 0
HPV39* HR 1 1 0
HPV51* HR 1 6 0
HPV52* HR 1 4 0
HPV66** HR 2 1 0
HPV68* Intermediate 0 2 0
HPV53 Intermediate 1 11 0
HPV6 LR 0 1 0
HPV54 LR 0 1 0
HPV69/71 LR 1 0 0
HPV74 LR 1 1 0
HPVX 2 2 0
HPV DNA negative 56 3 0
no result (sample failed) 19 2 0
Total 89 44 3
*HC2 and Cervista target types; **Cervista target type; HPVX: HPV DNA was detected by LiPA, but could not be correlated to a specific type; +ve: positive; −ve: negative.
Table 6 Relative sensitivity, relative specificity, PPV and NPV of the Cervista HPV HR test and HC2 for detecting CIN3+
within various cytology groups
CERVISTA
Relative sensitivity Relative specificity PPV NPV
CIN 3+ % 95% CI % 95% CI % 95% CI % 95% CI
ASC-H, AGUS (Pap III) 80.0% (29.9-98.9) 100.0% (54.6-100) 100.0% (39.6-100) 50.0% (26.7-97.3)
LSIL, HSIL (Pap IIID) 100.0% (80.0-100) 17.5% (7.9-33.4) 37.7% (25.1-52.1) 100.0% (56.1-100)
HSIL, CIS (Pap IVa) 96.6% (87.0-99.4) NA 84.8% (73.4-92.1) NA
HSIL, CIS, Micro (IVb) 100.0% (19.8-100) NA 100% (19.8-100) NA
Microinvasive (Pap V) 100.0% (30.1-100) NA 100% (30.1-100) NA
AGUS+ (≥Pap III) 96.6% (89.7-99.1) 15.7% (7.5-29.1) 66.4% (57.5-74.4) 72.7% (39.3-92.7)
HSIL+ (≥Pap IVa) 96.8% (88.0-99.4) NA 85.9% (75.2-92.7) NA
HR HC2
Relative sensitivity Relative specificity PPV NPV
CIN 3+ % 95% CI % 95% CI % 95% CI % 95% CI
ASC-H, AGUS (Pap III) 80.0% (29.9-98.9) 100.0% (54.6-100) 100.0% (39.6-100) 50.0% (26.7-97.3)
LSIL, HSIL (Pap IIID) 100.0% (80.0-100) 10.0% (3.3-24.6) 35.7% (23.7-49.7) 100.0% (39.6-100)
HSIL, CIS (Pap IVa) 100.0% (92.3-100) NA 85.3% (74.2-92.3) NA
HSIL, CIS, Micro (IVb) 100.0% (19.8-100) NA 100% (19.8-100) NA
Microinvasive (Pap V) 100.0% (30.1-100) NA 100% (30.1-100) NA
AGUS+ (≥Pap III) 98.9% (92.9-99.9) 9.8% (3.7-22.2) 65.4% (56.6-73.3) 83.3% (36.5-99.1)
HSIL+ (≥Pap IVa) 100.0% (92.8-100) NA 86.3% (75.8-92.9) NA
+: and higher.
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combination with an individual-reaction FOZ value of
>1.93 if all three probe sets yielded a positive test result.
We here examined the cut-off FOZ ratio ≥1.525 without
any additional criteria and a FOZ ratio of ≥1.525 or <1.525
with an individual-reaction FOZ value of ≥4.0. As shown in
Table 7, HPV prevalence measured by the Cervista HPV
HR test in the LBC normal category decreased to 6.7% and
6.1%, respectively, whereas the kappa values increased to
0.73 when using the two different FOZ cut-off values. Rela-
tive sensitivity for the detection of CIN3+ was not affected
by the modification of the FOZ-values.
Discussion
This study compares the Cervista HPV HR test to the
HC2 test within a German routine cervical cancer
screening population of women aged ≥30 years initially
screened by LBC. Overall the HR HPV prevalence was
27.8% and 25.2% for Cervista HPV HR and HC2, re-
spectively. Due to the inclusion of 60 additional patients
with CIN3+, the overall prevalence is higher than HR
HPV prevalence rates of ~9% previously reported for a
comparable screening population with participants aged
≥30 years [14]. The overall agreement of the HPV-tests
was excellent (κ = 0.8). Relative performance of each
HPV test was assessed by calculating relative sensitivity
and specificity based on histologically confirmed CIN3+ as
positive clinical outcome. The relative sensitivities deter-
mined for both tests in women with abnormal cytology
(AGUS+) were comparable, with 96.6% for Cervista and
98.9% for HC2. Although relative specificity was better for
the Cervista HPV HR test (15.7%) than for HC2 (9.8%),
the difference was not significant (p value = 0.14), which is
supported by the results obtained from our ratio analysis.
Our findings confirm the results of previous publications,
which compared the performances of the Cervista HPV
HR test and the HC2 tests and showed no significant dif-
ferences in sensitivities detecting histologically confirmed
high grade lesions (CIN2+ or CIN3+) [12,16,17]. These
studies also demonstrated differences in specificities in
favour for the Cervista HPV HR test, however only
Belinson et al. was able to show that this difference was of
statistical significance [17].
Interestingly, we found a significant difference between
HR HPV prevalences detected by Cervista and HC2 in the
cytology normal (NILM; negative for intraepithelial lesion
or malignancy) group (p < 0.0001; Table 3). In order to re-
solve discordant results genotyping by INNO-LiPA Extra
was performed. LiPA genotyping has previously been used
as an adjudicating assay in test comparison studies [26,27]
because of its excellent analytical sensitivity of 20 to 70
copies per assay [28]. In line with previous studies (sum-
marized by [29]) our discrepancy analysis demonstrated
substantial cross-reactivity of HC2 with non-target HPV
types (n = 16 versus n = 3 for HC2 and Cervista, respect-
ively). Furthermore, discrepancy analysis revealed a high
false positive rate for Cervista using the currently ap-
proved cut-off values (n = 56 for Cervista versus n = 3 for
HC2; Table 5). This result, however, is not in line with pre-
vious studies demonstrating a tendency of a lower or no
difference in the HR HPV prevalence rate for Cervista in
comparison to HC2 in women with NILM cytology
[12-17]. This disagreement with previous reports might,
however reflect differences in study design [12,13,16,17],
age range of participants [12,13,15-17] or overall HR HPV
prevalence rates [14]. Nonetheless, our data confirm a
commentary, which critically discusses the high false posi-
tive detection rate of the Cervista HPV HR test in cyto-
logically normal specimens of women ≥ 30 years of age by
evaluating data published with the Cervista HPV HR test
package insert [30]. By applying modified cut-off values
Figure 2 Ratio of specificities of Cervista and HC2 as a function
of HR HPV prevalence.
Table 7 Different cut-off values for Cervista HPV HR test in LBC-normal samples
CERVISTA cut-off
FOZ ratio FOZ value CER+ve % HC2+ve % κ (95% CI)
≥1.525 or <1.525 ≥1.93 10.8% 5.7% 0.52 (0.42-0.61)
≥1.525 6.7% 5.7% 0.73 (0.64-0.81)
≥1.525 or <1.525 ≥4 6.1% 5.7% 0.73 (0.65-0.81)
+ve: positive.
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(increase of the individual-reaction FOZ value from ≥1.93
to ≥4 or the elimination of the individual-reaction FOZ
value), which were optimised for the detection of CIN3+
lesions and not HPV DNA in cytologically normal sam-
ples, we were able to dramatically reduce the false-positive
rate of the Cervista HPV HR test in the Pap normal group
resulting in a similar HR HPV-prevalence as detected by
HC2, while the relative sensitivity for the detection of high
grade disease (CIN3+) remained unaltered. Therefore, a
re-adjustment of the manufacturer s cut-off values for the
use of the Cervista HPV HR test in primary screening may
be considered, but further population-based studies are
necessary to confirm our finding. Studies evaluating the
company set cut-off values for the detection of disease
have previously been performed for other HPV tests
including HC2 where adjustment led to an increased spe-
cificity of disease detection and fewer false-positive test
results [31]. It is worth noting that current clinical routine
in Germany requires ancillary HPV testing only for
patients with abnormal or borderline cytology results
(PapIIw, PapIII and PapIIID). Importantly, as around 50%
of ASC-US specimens will be tested HR HPV positive
[32], the accurate early detection of relevant infections by
non-invasive and cost-effective tests is fundamental. For
the ASC-US category, we demonstrate that the perform-
ance of the Cervista HPV HR test was non-inferior to
HC2 and rather showed a higher detection rate than HC2.
This is in line with previous studies demonstrating a high
sensitivity for HR HPV detection and a lower false positive
rate as compared to HC2 in ASC-US specimens
[13,14,18,19,21]. Finally, split sample test comparison re-
sults of multiple HPV tests other than Cervista have re-
cently been published from the Horizon study where the
authors found substantial disagreement between HPV
tests especially in women aged 30 65 years. These dis-
agreements were attributed to screening false positives and
were probably based on the different assay designs [33].
Conclusions
We evaluated the performance of the Cervista HPV HR
test using residual LBC specimens of a German routine
cervical cancer screening population. We demonstrate
that the Cervista HPV HR test would be appropriate to
be used in primary routine cervical cancer screening
after cut-off adjustment or in its current format adjunct-
ive to cytology for detection of high grade cervical
intraepithelial neoplasia in women with abnormal (ASC-
US+) cytology, yielding similar HR HPV detection rates
and relative sensitivity and specificity as the HC2 test.
The presence of an internal control as provided by the
Cervista HPV HR assay might be responsible for the re-
duced false negative test results within discrepant sam-
ples, as compared to the HC2 test system, which lacks
such a control. Another major advantage of the Cervista
HPV HR test is the automated integrated DNA extrac-
tion step using the HTA system from Hologic, which
avoids extra working steps resulting in a minimised risk
of sample contamination prior to testing.
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